Table 1 Demographics of the 5000 patients
No. of cases5000 (%)No. of cases5000 (%)
SexComorbids
    Male1050 (21.0)Hepatic disorder4846 (96.9)
    Female3950 (79.0)    None
Age    Yes154 (3.1)
    ⩽29 years260 (5.2)Cardiac disorder
    30–39 years355 (7.1)    None4874 (97.5)
    40–49 years723 (14.5)    Yes126 (2.5)
    50–59 years1656 (33.1)Diabetes mellitus
    60–69 years1434 (28.7)    None4532 (90.6)
    70 years⩽572 (11.4)    Yes468 (9.4)
    Mean (SD) (years)55.1 (12.9)Respiratory disease
Steinbrocker stage classification    None4765 (95.3)
    I272 (5.4)    Yes235 (4.7)
    II1150 (23.0)Haematological disease
    III1812 (36.2)    None4938 (98.8)
    IV1766 (35.3)    Yes62 (1.2)
Steinbrocker functional classificationAllergy
    I411 (8.2)None4369 (89.1)
    II2784 (55.7)Yes537 (10.9)
    III1619 (32.4)Unknown94
    IV186 (3.7)History of tuberculosis infection
Duration of rheumatoid arthritisNone4742 (94.8)
    <3 years882 (18.4)Yes258 (5.2)
    3–5 years612 (12.8)Methotrexate dose
    5–10 years    10–15 years1287 (26.9)894 (18.7)<6 mg/week6–8mg/week121 (2.4)4338 (86.8)
    15 years⩽1111 (23.2)8 mg/week<541 (10.8)
    Unknown214Mean (SD) (mg/week)7.3 (2.0)
    Mean (SD) (years)9.9 (8.1)Serum creatinine
Body weight<1.0 mg/dL4871 (97.4)
    <40 kg245 (4.9)1.0 mg/dL ⩽128 (2.6)
    40–50 kg1447 (29.0)Unknown1
    50–60 kg1978 (39.6)Concomitant glucocorticosteroid
    60–70 kg962 (19.3)None583 (11.7)
    70 kg⩽358 (7.2)Yes4417 (88.3)
    Unknown10Participating to infliximab clinical trials
    Mean (SD) (kg)53.9 (10.1)None4948 (99.0)
Yes52 (1.0)